Cargando…

Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma

Targeted therapy and immunotherapy have revolutionized the treatment of metastatic skin melanoma but around half of all patients develop resistance early or late during treatment. The situation is even worse for patients with metastatic uveal melanoma (UM). Here we hypothesized that the immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Sah, Vasu R., Karlsson, Joakim, Jespersen, Henrik, Lindberg, Mattias F., Nilsson, Lisa M., Ny, Lars, Nilsson, Jonas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245557/
https://www.ncbi.nlm.nih.gov/pubmed/34753889
http://dx.doi.org/10.1097/CMR.0000000000000791
_version_ 1784738763108253696
author Sah, Vasu R.
Karlsson, Joakim
Jespersen, Henrik
Lindberg, Mattias F.
Nilsson, Lisa M.
Ny, Lars
Nilsson, Jonas A.
author_facet Sah, Vasu R.
Karlsson, Joakim
Jespersen, Henrik
Lindberg, Mattias F.
Nilsson, Lisa M.
Ny, Lars
Nilsson, Jonas A.
author_sort Sah, Vasu R.
collection PubMed
description Targeted therapy and immunotherapy have revolutionized the treatment of metastatic skin melanoma but around half of all patients develop resistance early or late during treatment. The situation is even worse for patients with metastatic uveal melanoma (UM). Here we hypothesized that the immunotherapy of therapy-resistant skin melanoma or UM can be enhanced by epigenetic inhibitors. Cultured B16F10 cells and human UM cells were treated with the histone deacetylase inhibitor (HDACi) entinostat or BETi JQ1. Entinostat-induced HLA expression and PD-L1, but JQ1 did not. A syngeneic mouse model carrying B16-F10 melanoma cells was treated with PD-1 and CTLA4 inhibitors, which was curative. Co-treatment with the bioavailable BETi iBET726 impaired the immunotherapy effect. Monotherapy of a B16-F10 mouse model with anti-PD-1 resulted in a moderate therapeutic effect that could be enhanced by entinostat. Mice carrying PD-L1 knockout B16-F10 cells were also sensitive to entinostat. This suggests HDAC inhibition and immunotherapy could work in concert. Indeed, co-cultures of UM with HLA-matched melanoma-specific tumor-infiltrating lymphocytes (TILs) resulted in higher TIL-mediated melanoma killing when entinostat was added. Further exploration of combined immunotherapy and epigenetic therapy in metastatic melanoma resistant to PD-1 inhibition is warranted.
format Online
Article
Text
id pubmed-9245557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92455572022-07-01 Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma Sah, Vasu R. Karlsson, Joakim Jespersen, Henrik Lindberg, Mattias F. Nilsson, Lisa M. Ny, Lars Nilsson, Jonas A. Melanoma Res Original Articles: Translational Research Targeted therapy and immunotherapy have revolutionized the treatment of metastatic skin melanoma but around half of all patients develop resistance early or late during treatment. The situation is even worse for patients with metastatic uveal melanoma (UM). Here we hypothesized that the immunotherapy of therapy-resistant skin melanoma or UM can be enhanced by epigenetic inhibitors. Cultured B16F10 cells and human UM cells were treated with the histone deacetylase inhibitor (HDACi) entinostat or BETi JQ1. Entinostat-induced HLA expression and PD-L1, but JQ1 did not. A syngeneic mouse model carrying B16-F10 melanoma cells was treated with PD-1 and CTLA4 inhibitors, which was curative. Co-treatment with the bioavailable BETi iBET726 impaired the immunotherapy effect. Monotherapy of a B16-F10 mouse model with anti-PD-1 resulted in a moderate therapeutic effect that could be enhanced by entinostat. Mice carrying PD-L1 knockout B16-F10 cells were also sensitive to entinostat. This suggests HDAC inhibition and immunotherapy could work in concert. Indeed, co-cultures of UM with HLA-matched melanoma-specific tumor-infiltrating lymphocytes (TILs) resulted in higher TIL-mediated melanoma killing when entinostat was added. Further exploration of combined immunotherapy and epigenetic therapy in metastatic melanoma resistant to PD-1 inhibition is warranted. Lippincott Williams & Wilkins 2021-11-10 2022-08 /pmc/articles/PMC9245557/ /pubmed/34753889 http://dx.doi.org/10.1097/CMR.0000000000000791 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles: Translational Research
Sah, Vasu R.
Karlsson, Joakim
Jespersen, Henrik
Lindberg, Mattias F.
Nilsson, Lisa M.
Ny, Lars
Nilsson, Jonas A.
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
title Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
title_full Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
title_fullStr Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
title_full_unstemmed Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
title_short Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
title_sort epigenetic therapy to enhance therapeutic effects of pd-1 inhibition in therapy-resistant melanoma
topic Original Articles: Translational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245557/
https://www.ncbi.nlm.nih.gov/pubmed/34753889
http://dx.doi.org/10.1097/CMR.0000000000000791
work_keys_str_mv AT sahvasur epigenetictherapytoenhancetherapeuticeffectsofpd1inhibitionintherapyresistantmelanoma
AT karlssonjoakim epigenetictherapytoenhancetherapeuticeffectsofpd1inhibitionintherapyresistantmelanoma
AT jespersenhenrik epigenetictherapytoenhancetherapeuticeffectsofpd1inhibitionintherapyresistantmelanoma
AT lindbergmattiasf epigenetictherapytoenhancetherapeuticeffectsofpd1inhibitionintherapyresistantmelanoma
AT nilssonlisam epigenetictherapytoenhancetherapeuticeffectsofpd1inhibitionintherapyresistantmelanoma
AT nylars epigenetictherapytoenhancetherapeuticeffectsofpd1inhibitionintherapyresistantmelanoma
AT nilssonjonasa epigenetictherapytoenhancetherapeuticeffectsofpd1inhibitionintherapyresistantmelanoma